Determining Molecular Drivers of Radiation Dermatitis


About this study

The purpose of this study is to collect (i) pre-treatment (at the time of breast cancer surgery) normal skin and (ii) on-treatment (around the third week of treatment with breast radiation) irradiated skin with clinical hallmarks of radiation dermatitis (erythema and/or dry desquamation, documented by a photograph and graded by clinical criteria).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients receiving standard-of-care postoperative radiation therapy (2-2.7 Gy per fraction) to the breast and/or chest wall for breast cancer treatment.
  • Tissue diagnosis of breast cancer.
  • Age ≥ 18 years
  • Signed informed consent.
  • CBC within normal limits within the preceding 2 weeks.

Exclusion Criteria:

  • Induction chemotherapy or biologic therapy.
  • Concurrent chemotherapy or biologic therapy.
  • Autoimmune disease with skin manifestations – psoriasis, dermatomyositis, scleroderma, eczema, polymyositis.
  • Allergy to lidocaine anesthesia.
  • Known bleeding diathesis (anticoagulation with warfarin, coagulation/bleeding disorders, vitamin C or K deficiency, thrombocytopenia).
  • History of keloids or easy scarring.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Laura Vallow, M.D.

Open for enrollment

Contact information:

Anna Harrell B.S., M.P.H., CCRP

More information


Publications are currently not available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions